Clinical trials: Koch's Disease
Tuberculosis, HIV
DNA Sequencing of MDR TB in Eastern Siberia
This is protocol is generated in response to the exploratory R21 from the National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID) for US-Russia collaborative research in HIV/tuberculosis…
- Trial name
- NCT02508610
- Where
- Russia
- Volunteers
- 630 people
- Sponsor
- University of Virginia
HIV Infected Population With Latent Tuberculosis
Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers
People with human immunodeficiency virus (HIV) often take several medicines to control HIV. Dolutegravir and darunavir boosted with cobicistat are HIV medicines that people may take.
- Trial name
- NCT02771249
- Testing
- rifapentene (RPT), darunavir/cobicistat (DRV/c), Isoniazid (INH)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Tuberculosis, Pulmonary
Novel Triple-dose Tuberculosis Retreatment Regimens: How to Overcome Resistance Without Creating More
Drug-resistance is a major challenge for tuberculosis (TB) care programs. The new WHO guideline recommends adding levofloxacin in previously treated patients with isoniazid-resistant rifampicin-susceptible TB.
- Trial name
- TriDoRe (NCT03862248)
- Testing
- 6EH³RZ, 6EHR³Z, 6EHRZLfx
- Where
- Bangladesh
- Sponsor
- Institute of Tropical Medicine, Belgium
Latent Tuberculosis Infection
Latent Tuberculosis in Type 2 Diabetes
The patients with poorly controlled DM underwent LTBI screening by using QuantiFERON (QFT). QFT-positivity predictors were evaluated.
- Trial name
- TB (NCT06874725)
- Testing
- Rifapentine and Isoniazid for 3 months, Isoniazid (INH) daily for 9 months
- Where
- Taiwan
- Volunteers
- 552 people
- Sponsor
- Taichung Veterans General Hospital
Silicosis Tuberculosis
Short Course Rifapentine and Isoniazid for the Preventive Treatment of Tuberculosis(SCRIPT-TB)
Tuberculosis (TB) remains the most important infectious disease in the world. Preventive treatment plays an important role in successful control of TB.
- Trial name
- TB (NCT03900858)
- Testing
- Isoniazid；Rifapentine
- Where
- China
- Volunteers
- 566 people
- Sponsor
- Huashan Hospital
Tuberculosis, Multidrug-Resistant
Clinical Evaluation of tNGS for Diagnosis of DR-TB
Current rapid molecular assays for detection of drug-resistant TB from direct clinical samples have important limitations. They are not suited for high-throughput settings; can only be used to detect a limited number of target…
- Trial name
- Seq&Treat (NCT04239326)
- Testing
- targeted Next Generation Sequencing (tNGS)
- Where
- 3 sites in Georgia, India and 1 more
- Volunteers
- 800 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Chronic Liver Disease With Tuberclosis
Efficacy and Safety of Modified Anti-tubercular Regimens in Treatment of Tuberculosis in Patients With Underlying Compensated and Decompensated Chronic Liver Disease
During the Study: Subject is required to visit every week for the first 2 months and then every month till completion of study or as and when required The usual symptomatic and supportive treatment of Chronic Liver Disease…
- Trial name
- NCT01677871
- Testing
- 2HRZE/4HR, 2HRLE/4HR, 9HLE
- Where
- India
- Volunteers
- 120 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Lung Diseases, Tuberculosis
Promoting Adherence to TB Regimens in Latino Adolescents
To test a public health model of screening, preventive isoniazid treatment, and adherence counseling plus medical education of primary care clinicians to enhance their skills and attention to TB control.
- Trial name
- NCT00005738
- Sponsor
- San Diego State University
Tuberculosis
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
The objective of this project is to demonstrate safety, immunogenicity and improved efficacy of the new live attenuated M. tuberculosis vaccine called MTBVAC in a Phase 3 efficacy trial in HIV-uninfected infants born to…
- Trial name
- MTBVACN3 (NCT04975178)
- Testing
- MTBVAC, BCG
- Where
- South Africa
- Volunteers
- 7,120 people, healthy volunteers welcome
- Sponsor
- Biofabri, S.L
Rifampicin-resistant Tuberculosis
French National Cohort of Patients With Rifampicin-Resistant Tuberculosis
A major obstacle in the fight against multidrug-resistant tuberculosis is its treatment. In 2021, only 60% of patients with MDR/RR tuberculosis who received treatment globally were successfully cured, while 12% succumbed to the…
- Trial name
- CONTRol-TB (NCT06565806)
- Volunteers
- 300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Tuberculosis
Multicenter Trial for the Evaluation of a Fixed Dose Combined Tablet for the Treatment of Pulmonary Tuberculosis
The use of fixed-dose combined (FDC) drugs in the treatment of tuberculosis by National Tuberculosis Programmes has been recommended by both the International Union Against Tuberculosis and Lung Disease (The Union) and the World…
- Trial name
- NCT00216333
- Testing
- combined fixed dose combination
- Where
- 9 sites in Algeria, Bolivia and 7 more
- Volunteers
- 1,500 people
- Sponsor
- International Union Against Tuberculosis and Lung Diseases
Immune Modulation, Tuberculosis
CD8 Reactivity to Microorganisms in Blood and Breast Milk
Background: When a person is exposed to something that causes an infection, the body sends a type of cell called CD8 T cells to attack it. Those cells are also found in breast milk.
- Conditions
- Immune Modulation, Tuberculosis, Leprosy, Pertussis
- Trial name
- NCT03084614
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis
Application of GeneXpert on Bronchoscopic Samples in the Clinical Management of Patients Suspicious of TB
This is a case control observational study using Bronchial-alveolar lavage (BAL) as specimen for GeneXpert, a real time polymerase chain reaction (PCR) test for detection of tuberculosis (TB).
- Trial name
- NCT02619240
- Testing
- bronchoscopy
- Where
- Hong Kong
- Volunteers
- 200 people
- Sponsor
- Chinese University of Hong Kong
Tuberculosis
Xpert Active Case-finding Trial 3 (XACT-3)
TB remains the foremost infectious disease killer globally. A startling statistic is that two out of every five TB cases globally (40%) remain undiagnosed and untreated.
- Trial name
- XACT-3 (NCT04303104)
- Testing
- GeneXpert Edge, GeneXpert Ultra
- Where
- 4 sites in Mozambique, South Africa and 2 more
- Volunteers
- 3,523 people
- Sponsor
- University of Cape Town
HIV Infections, Tuberculosis
Characteristics and Prevalence of Tuberculosis and HIV in Masiphumelele Township, Cape Town, South Africa
The purpose of this study is to determine the number of people infected with tuberculosis (TB) in the Masiphumelele Township of Cape Town, South Africa, a community with high rates of TB and HIV.
- Trial name
- NCT00346476
- Where
- 2 sites in South Africa
- Volunteers
- 1,250 people, healthy volunteers welcome
- Sponsor
- CIPRA SA
Maternal and Child Health
Impact of Vitamin D Supplementation on Fetomaternal Outcomes in LTBI Pregnant Females
The goal of this randomized controlled trial is to see the effect of vitamin D supplementation on fetomaternal outcomes in pregnant females with Latent Tuberculosis infection The main question[s] it aims to answer are: If Vitamin…
- Trial name
- RCT (NCT06354621)
- Testing
- Vitamin-D supplementation
- Where
- Pakistan
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- University of the Punjab
Tuberculosis
Can Screening People Registering With Primary Care Improve the Detection of Tuberculosis?
This randomised controlled trial tests whether screening people registering with general practices cost-effectively increases the detection of tuberculosis. The study objectives are to: 1.
- Trial name
- NCT00214708
- Testing
- Screening for Tuberculosis
- Where
- United Kingdom
- Sponsor
- Barts & The London NHS Trust
HIV Infections, TB
A Study of MVA85A, in Asymptomatic Volunteers Infected With TB, HIV or Both
This study is designed to evaluate the safety of MVA85A in asymptomatic volunteers in South Africa who are infected with M.tb, HIV or both.
- Trial name
- NCT00480558
- Testing
- MVA 85A
- Where
- South Africa
- Volunteers
- 48 people
- Sponsor
- University of Oxford
Kidney Transplant Recipient
Isoniazid (INH) Treatment Based on ELISPOT Assay
It has been recommended that all transplant recipients undergo a tuberculin skin test (TST) before transplantation. However, the ability of TST to diagnose latent tuberculosis infection (LTBI) in transplant candidates has been…
- Trial name
- NCT01087190
- Testing
- Isoniazid treatment
- Where
- South Korea
- Volunteers
- 831 people
- Sponsor
- Asan Medical Center
Drug-Induced Liver Injury, Anti-Tuberculous Drug Reaction
Assessing Antibiotic Induced Liver Injury for Stratification of Tuberculosis Patients
A panel of highly sensitive circulating biomarkers for acute liver injury have been identified and demonstrated to identify liver injury on first presentation to hospital before standard tests are elevated in patients with…
- Conditions
- Drug-Induced Liver Injury, Anti-Tuberculous Drug Reaction, Tuberculosis
- Trial name
- ALISTER (NCT03211208)
- Where
- United Kingdom
- Volunteers
- 194 people
- Sponsor
- University of Edinburgh
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.